Bulgaria vs North Macedonia: Prevalence rate of hypertension in men aged 30-79
Bulgaria
49.4
in 2019
North Macedonia
49.4
in 2019
Bulgaria rank
13th
North Macedonia rank
13th
Prevalence rate of hypertension in men aged 30-79 over time
- Bulgaria
- North Macedonia
How they compare
Bulgaria currently reports 49.4 against 49.4 in North Macedonia, a difference of 0.
Across all 30 years both countries report, North Macedonia has been ahead every year.
Bulgaria ranks 13th and North Macedonia ranks 13th of 195 countries.
North Macedonia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bulgaria | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 47.91 | 48.18 | 0.27 | North Macedonia |
| 2000s | 48.31 | 48.52 | 0.21 | North Macedonia |
| 2010s | 49.27 | 49.32 | 0.05 | North Macedonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Bulgaria or North Macedonia?
- Bulgaria, at 49.4 against 49.4 in North Macedonia as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Bulgaria and North Macedonia?
- 0, with Bulgaria ahead.
- How many years of comparable data are there for Bulgaria and North Macedonia?
- 30 years are reported by both, from 1990 to 2019.
- How do Bulgaria and North Macedonia rank globally for prevalence rate of hypertension in men aged 30-79?
- Bulgaria ranks 13th and North Macedonia ranks 13th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.